Navigation Links
3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
Date:8/15/2011

MENLO PARK, Calif., Aug. 15, 2011 /PRNewswire/ -- 3-V Biosciences, Inc. announced today the appointment of George W. Kemble, PhD as Chief Scientific Officer.

(Logo:  http://photos.prnewswire.com/prnh/20100513/LA04336LOGO)

"We are very pleased to have George as the newest member of the 3-V senior management team," said Merdad V. Parsey, MD, PhD, 3-V's Chief Executive Officer.  "George's extensive experience in drug discovery and development, as well as virology and host-cell biology, brings additional strength to the 3-V team and will further our efforts in this novel area."

Prior to joining 3-V Biosciences, Dr. Kemble was with MedImmune, Inc., a subsidiary of Astra-ZenecaPLC, where he most recently served as Senior Vice President of R&D and Head of Research.  During his tenure, Dr. Kemble was responsible for the research and development of multiple products, including the successful launch of FluMist®, the first innovation in influenza vaccines in over 60 years.  The research organization for which he was responsible included over 700 scientists in Maryland, California and Cambridge, England, with expertise in research biology, lead generation and translational science in the areas of infectious diseases, oncology, inflammatory, respiratory, autoimmune diseases, neuroscience, cardiovascular and gastrointestinal indications.  Dr. Kemble began his research career as a staff scientist at Aviron, which was later acquired by MedImmune.  Dr. Kemble received a BS from the University of Santa Clara and a PhD from Stanford University and did his post-doctoral training at UCSF, where he worked on a number of different human viruses.

"I'm very excited by the important projects we have in front of us," said Dr. Kemble.  "Our approach to combating these pathogens is highly innovative, and I am looking forward to continuing to grow our organization's expertise at developing these impactful medicines."  

About 3-V Biosciences3-V Biosciences, Inc. is a privately-held biopharmaceutical company dedicated to discovering, developing and ultimately commercializing novel antiviral therapeutics that target host cell factors required for viral infection, thereby avoiding many of the shortcomings of traditional pathogen-directed approaches.  The company is located in Menlo Park, California and is financed by The Column Group, Kleiner Perkins Caufield&Byers, and New Enterprise Associates.

For additional information on 3-V Biosciences, please visit www.3vbio.com.Contact informationStephen R. BradyChief Business Officer650-561-8600
'/>"/>

SOURCE 3-V Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- The report "Cryocooler Market by Type ... Support, Product Repairs & Refurbishment, Preventive Maintenance, and Customer ... published by MarketsandMarkets, the global market is expected to ... CAGR of 7.29% between 2016 and 2022. ... spread through 159 Pages and in-depth TOC on  "Cryocooler ...
(Date:4/28/2016)... ... April 28, 2016 , ... Connecticut Innovations (CI), ... today announced the launch of VentureClash , a $5 million global investment ... “VentureClash looks to attract the best early-stage companies here in Connecticut, around the ...
(Date:4/28/2016)... ... 28, 2016 , ... As part of an ongoing global ... expanding its LATAM network and logistics capabilities. Enhancements have been made to ... trial projects. , The expansion will provide unmatched clinical trial logistics services for ...
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... Cambridge ... by semantic web technology, today announced that it has been named to The Silicon ... sciences, financial services and other markets, Cambridge Semantics serves the needs of end users ...
Breaking Biology Technology:
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
(Date:3/15/2016)... JERUSALEM , March 15, 2016 ... Jerusalem , the technology-transfer company of the Hebrew University, ... developer of remote sensing technology of various human biological ... funding, raising $2.0 million from private investors. ... technology, based on the detection of electromagnetic emissions from ...
(Date:3/10/2016)... PUNE, India , March 10, 2016 ... to a new market research report "Identity and Access ... SSO, & Audit, Compliance, and Governance), by Organization Size, ... Forecast to 2020", published by MarketsandMarkets, The market is ... to USD 12.78 Billion by 2020, at a Compound ...
Breaking Biology News(10 mins):